CATXPerspective Therapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Perspective Therapeutics, Inc. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CATXEsta | $125M#8 | — | 0.4x#1 | 87.2x#6 | — | -30.1%#12 | -7919.4%#7 | -31.8%#3 | -41.0%#3 | — | -59.9%#2 | — |
| CUE | $154M#1 | — | 66.7x#14 | 5.6x#3 | 195.7%#2 | 34.6%#2 | -96.7%#2 | -1151.6%#14 | — | — | — | — |
| KRSA | $147M#2 | — | 28.9x#13 | 70.9x#5 | 3.7%#5 | -15.4%#11 | -239.8%#3 | -69.4%#8 | -69.1%#4 | — | — | — |
| RNA | $145M#3 | — | 0.7x#5 | — | — | — | — | 0.0%#2 | — | — | — | — |
| PYXS | $142M#4 | — | 12.4x#12 | 10.3x#4 | -14.2%#7 | -3.0%#9 | -609.2%#5 | -696.0%#13 | — | — | — | — |
| ZNTL | $135M#5 | — | 0.9x#7 | — | -100.0%#8 | 17.4%#4 | — | -95.4%#11 | — | — | — | — |
| SPRB | $131M#6 | — | 1.6x#8 | — | -100.0%#8 | 26.5%#3 | — | -46.5%#6 | — | — | — | — |
| SCNX | $131M#7 | — | 2.0x#9 | 304.5x#7 | 215.9%#1 | -404.5%#14 | -9867.9%#8 | -64.8%#7 | -73.5%#5 | 4#1 | — | 11.3%#1 |
| FHTX | $119M#9 | — | — | 3.9x#2 | 36.8%#3 | 14.2%#5 | -279.5%#4 | — | — | — | — | — |
| HURA | $116M#10 | — | 6.3x#10 | — | — | -34.8%#13 | — | -167.6%#12 | -0.1%#2 | — | -28.9%#1 | — |
| NERV | $113M#11 | — | — | — | — | -20492.7%#15 | — | — | — | — | — | — |
| NKTX | $108M#12 | — | 0.4x#2 | — | — | 4.3%#7 | — | -42.0%#5 | — | — | — | — |
| OKUR | $107M#13 | — | 0.6x#3 | — | — | -13.0%#10 | — | -34.6%#4 | — | — | — | — |
| ANIX | $107M#14 | — | 7.4x#11 | 509.9x#8 | 0.0%#6 | 13.0%#6 | -5571.9%#6 | -75.5%#9 | -87.0%#6 | — | — | — |
| IMUX | $100M#15 | 3.6x#1 | 0.8x#6 | — | — | 3.3%#8 | — | -76.2%#10 | — | — | — | — |
| ORGO | $95M#16 | — | 0.6x#4 | 0.2x#1 | 17.0%#4 | 4011.1%#1 | 7.9%#1 | 25.0%#1 | 23.2%#1 | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. Esta tabla agotó el tiempo durante su construcción, por lo que cubre parte del grupo; los rangos son solo dentro de las filas mostradas y se completará en breve. Table built 2026-11-03.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice